骨転移を合併する前立腺癌にかんする臨床的研究 第1編: 臨床的観察とホルモン療法の遠隔成績

Abstract

1. Sixty-three carcinoma of the prostate were experienced for past 7 years and 8 months, April 1964 to Dec. 1971, and followed up. Twenty-five of them (39.7 %) had metastatic bone lesions. Of twenty-nine cases over 71 years of age, 15 (51.7 %) had bone metastasis. 2. The patients without bone lesions mostly visited complaining of dysuria, and 48 % of those with bone lesions complained of lumbago or neuralgic pain of the lower extremities. 3. 37% of those having the bone lesions visited the clinic after spending more than three years from the onset of symptoms, whereas 23.6 % of the non-metastatic group visited after 3 years. 4. The metastatic group showed hydronephrosis or non-visualizing kidney in 10 cases (43.5 %), whereas the non-metastatic group showed such abnormalities only in 8 (22.2%). 5. There was no difference of amount of residual urine between two groups. 6. Metastases were mostly to the lower vertebrae and pelvic bone (72 % in both), and the multiple lesions were seen in 28 %. 7. Histologically, bone metastasis was seen in 18 out of 45 adenocarcinomas (40 %) and in 3 out of 12 undifferentiated carcinomas (30 %). 8. The end results of the anti-androgen therapy expressed by the survival rate were 75.3 % in 3 years and 57.4 % in 5 years in the non-metastatic group which did not differ from the average survival rate of the same generation. 9. The survival rate of the metastatic group was 26.0 % in 2 years and 17.3% in 5 years. Two cases are still alive at 3.25 and 4.25 years. 10. Leading cause of death was cancer (75 %) in the metastatic group and cardiovascular diseases (50 %) in the non-metastatic group.